Instituto de Investigacion Sanitaria Fundacion para la Investigacion del Hospital Clinico de Valencia-INCLIVA
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
At Instituto de Investigacion Sanitaria Fundacion para la Investigacion del Hospital Clinico de Valencia-INCLIVA, research in this area focuses on therapeutic techniques and supportive care approaches for kidney disease and refractory heart failure. The trials are designed to better understand how treatments may improve fluid balance and sodium handling in patients with complex chronic conditions.
- Improving diuresis and natriuresis in chronic kidney disease
- Evaluating sodium removal through peritoneal dialysis
- Assessing treatment strategies for refractory heart failure
This work reflects a practical focus on optimizing everyday clinical management for patients who need better control of fluid overload and related symptoms.
Diseases - Neoplasms
The oncology research at this Valencia site includes studies in neoplasms, especially cancers with microsatellite instability-high or mismatch repair deficiency. These trials aim to test new treatment options and explore how targeted therapies may help patients with advanced solid tumors that are difficult to treat.
- Studying MSIhi and dMMR advanced solid tumors
- Exploring novel cancer therapy options alone or in combination
- Supporting treatment development for metastatic and unresectable cancer
The research is centered on improving outcomes for patients whose tumors carry specific DNA alterations and may respond differently to standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto de Investigacion Sanitaria Fundacion para la Investigacion del Hospital Clinico de Valencia-INCLIVA
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Oct 2020 | Jul 2026 |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2024-09-30 | 2025-12-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.